| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

12 November 2018

Oryzon announces First-Patient-in in ALICE: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Acute Myeloid Leukemia patients

2 November 2018

ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2018

26 October 2018

Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors

5-6 December 2018

2018 Citi Global Healthcare Conference

Lotte Hotel

New York

United States

14-15 November 2018

Jefferies London Healthcare Conference

London

United Kingdom

5-7 November 2018

24th Annual International Partnering Conference BIO-Europe-2018

Copenhagen

Denmark

23-24 October 2018

European Alzheimer’s Disease Consortium meeting

Barcelona

Spain

24-27 October 2018

11th Clinical Trials on Alzheimer's Disease, CTAD-2018

Congress Center

Barcelona

Spain

22 October 2018

Oryzon to present at upcoming international conferences

17 October 2018

ORYZON receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)

Pagination

First page «
Previous page ‹
Page 38
Page 39
Page 40
Page 41
Current page 42
Page 43
Page 44
Page 45
Page 46
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel